Radient Pharmaceuticals Drives Product Awareness and Education of Its Onko-Sure(R) IVD Cancer Test With the Launch of a New and Content Rich Product Website

The patient- and healthcare professional-focused site offers more in-depth product information for the Company's USFDA-approved Onko-Sure® In Vitro Diagnostic (IVD) cancer test, along with an expanded product 'resources' section that offers a technical documents area where users can easily access RPC's white papers, clinical trial data and information, product training presentations and published articles. Restructured product pages also make it more intuitive for the users to access important regulatory, technical and patient use information. The site includes a link to RPC's Investor Video Channel -- a recently launched investor-focused website that features videos communicating RPC's business model, target markets and international distribution, sales and growth strategy; RPC as an investment opportunity; updates and progress on RPC's portfolio of cancer diagnostic products, including its FDA-approved Onko-Sure® cancer test kit; and educational information specifically targeted towards patients, physicians and the healthcare community in general.

According to RPC's Executive Chairman and CEO Douglas MacLellan, "We are extremely thrilled to enhance our Onko-Sure® product website. Our focus was to create a site that not only reflects where we are as company today, but where we are headed in the future. Equally important, we wanted to provide a highly comprehensive and easy-to-use resource that provides patients and healthcare professionals with relevant, high-value information on our Onko-Sure® IVD cancer tests."

RPC's Onko-Sure® IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection and monitoring of the treatment and/or recurrence of various types of cancer. The test enables physicians and healthcare professionals to effectively detect and/or monitor certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure® is cleared by the US FDA for detection during colorectal cancer treatment and/or for recurrence monitoring in colorectal cancer patients and by Health Canada for the detection, treatment and/or recurrence monitoring of lung cancer.